- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Vycor Medical Reports Strong 2025 Earnings
Neurosurgical device maker sees 18% revenue growth, driven by international markets
Mar. 31, 2026 at 6:48pm
Got story updates? Submit your updates here. ›
Vycor's advanced medical devices leverage precision engineering to improve patient outcomes in neurosurgery.Boca Raton TodayVycor Medical, Inc., a Florida-based medical device company, announced its financial results for the year ended December 31, 2025. The company's Vycor Medical division, which produces the ViewSite Brain Access System (VBAS) for neurosurgeons, saw an 18% increase in revenue over 2024, with most of the growth coming from international markets.
Why it matters
Vycor's strong financial performance highlights the growing global demand for its minimally invasive neurosurgical technology, which has been validated through over 50 peer-reviewed studies demonstrating improved patient outcomes and reduced recovery times.
The details
The company's operating profit was $33,900 in 2025, compared to an operating loss of $9,145 in 2024. Vycor's non-GAAP operating profit was $145,881, up from $81,245 the prior year. The company also published seven new peer-reviewed studies on the VBAS system in 2025, bringing the total to 50 published papers.
- Vycor reported its full-year 2025 financial results on March 31, 2026.
The players
Vycor Medical, Inc.
A publicly traded medical device company that operates two business units: Vycor Medical, which produces the ViewSite Brain Access System (VBAS), and NovaVision, which offers vision rehabilitation therapies.
The takeaway
Vycor's ability to grow its revenue and profitability, while also advancing the clinical validation of its VBAS technology, positions the company well to continue expanding its global footprint in the neurosurgical device market.
